L-MTO-PE - a potential drug for cancer therapy

• Authors: K. Dzierzbicka , M. Gozdowska , A.M. Kolodziejczyk
• Languages of publication: PL

Abstracts

EN

Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a syntetic lipophilic analogue of muramyl dipeptide, stimulates monocytes/macrophages to kill a variety of tumor cells in vitro and in vivo. Encapsulation of MTP-PE into multilamellar liposomes (L-MTP-PE) was specifically designed for in vivo targeting to macrophages by i.v. infusion and is the only form of the drug currently available for clinical trials (CGP 19835A Lipid). L-MTP-PE is presently undergoing clinical trials in patients with recurrent osteosarcoma and melanoma. L-MTP-PE combined with other anticancer agents may thus improve long-term cure rates of patients with this diseases.

Keywords

EN

CANCER THERAPY

Discipline

• EXPERIMENTAL_BIOLOGY_&_MEDICINE: EXPERIMENTAL BIOLOGY & MEDICINE

• Journal: Postępy Higieny i Medycyny Doświadczalnej
• Year: 1997
• Volume: 51
• Issue: 2
• Pages: 227-236

Contributors

author

K. Dzierzbicka

author

M. Gozdowska

author

A.M. Kolodziejczyk

• Document Type: article
• Publication order reference: K.Dzierzbicka, ul. Przyjemna 2c/11, 80-054 Gdansk, Poland